{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:14:41Z","timestamp":1778782481735,"version":"3.51.4"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016579","name":"Amgen Astellas Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016579","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kaneka"},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009015","name":"Abbott Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015643","name":"Japan Lifeline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017090","name":"Sony","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cate"},{"DOI":"10.13039\/100019341","name":"Medtronic Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>18F-fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT) is a pivotal tool for diagnosing cardiac sarcoidosis, but its prognostic value during the phase of stable medical and device therapy after initiation of immunosuppressive therapy remains unclear. We aimed to evaluate the prognostic significance of cardiac FDG uptake in patients with cardiac sarcoidosis after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 79 patients who underwent FDG-PET\/CT\u2009\u2265\u200912 months after initiating immunosuppressive therapy (June 2013\u2013October 2023). Patients were categorized into the cardiac accumulation (+) and (-), and Cardiac metabolic activity (CMA) was also quantitatively measured. Major adverse cardiac events\u2014including cardiac death, ventricular arrhythmias, ICD therapy, and heart failure hospitalization\u2014were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients in the cardiac accumulation (+) had a higher 2-year incidence of major adverse cardiac events than those in the cardiac accumulation (-), as determined by Kaplan\u2013Meier analysis (log-rank P\u2009=\u20090.030), but FDG uptake was not identified as a predictor in Cox regression analysis. In long-term outcomes, the incidence of cardiac events tended to be higher in the cardiac accumulation (+) group, although this difference did not reach statistical significance (log-rank P\u2009=\u20090.078). Among patients with preserved left ventricular ejection fraction (LVEF \u226550%, independently associated with fewer events), annual cardiac event rates were similarly low regardless of uptake status (1.3% vs. 0.8%; log-rank P\u2009=\u20090.91). In 41 patients who underwent repeat PET imaging, CMA significantly decreased (median 4.83 to 0.82, P\u2009=\u20090.038). Among 23 patients without intensified immunosuppression despite uptake, it resolved spontaneously in 8 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Follow-up cardiac FDG uptake may be associated with an increased risk of short-term events but has limited value for predicting long-term prognosis. LVEF and the temporal dynamics of FDG uptake should be considered when managing cardiac sarcoidosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0347595","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:42:39Z","timestamp":1778780559000},"page":"e0347595","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of 18F-fluorodeoxyglucose uptake with cardiac events in cardiac sarcoidosis during outpatient follow-up after immunosuppression"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2924-3615","authenticated-orcid":true,"given":"Hideki","family":"Kawai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Sarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuchika","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-5366","authenticated-orcid":true,"given":"Masakazu","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"11","key":"pone.0347595.ref001","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of Sarcoidosis and Its Management","volume":"385","author":"M Drent","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0347595.ref002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2021.06.016","article-title":"Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review","volume":"28","author":"NA Gilotra","year":"2022","journal-title":"J Card Fail"},{"issue":"30","key":"pone.0347595.ref003","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/eurheartj\/ehae356","article-title":"Management of cardiac sarcoidosis","volume":"45","author":"R Sharma","year":"2024","journal-title":"Eur Heart J"},{"issue":"17","key":"pone.0347595.ref004","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehad067","article-title":"Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis","volume":"44","author":"J Lehtonen","year":"2023","journal-title":"Eur Heart J"},{"issue":"21","key":"pone.0347595.ref005","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001240","article-title":"Diagnosis and management of cardiac sarcoidosis: a scientific statement from the american heart association","volume":"149","author":"RK Cheng","year":"2024","journal-title":"Circulation"},{"issue":"36","key":"pone.0347595.ref006","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1093\/eurheartj\/ehac323","article-title":"Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry","volume":"43","author":"T Nabeta","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"pone.0347595.ref007","first-page":"133","article-title":"Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block","volume":"20","author":"Y Kato","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"pone.0347595.ref008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcmg.2016.05.009","article-title":"Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis","volume":"10","author":"GC Coleman","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"pone.0347595.ref009","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis\u3000- Digest Version","volume":"83","author":"F Terasaki","year":"2019","journal-title":"Circ J"},{"key":"pone.0347595.ref010","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jcmg.2020.11.016","article-title":"Pre-Treatment Myocardial 18FDG Uptake Predicts Response to Immunosuppression in Patients With Cardiac Sarcoidosis","volume":"14","author":"M Subramanian","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"pone.0347595.ref011","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jcmg.2024.05.013","article-title":"Risk stratification in cardiac sarcoidosis with cardiac positron emission tomography: a systematic review and meta-analysis","volume":"17","author":"TS Kafil","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"pone.0347595.ref012","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/ehf2.12853","article-title":"Diagnosis of isolated cardiac sarcoidosis based on new guidelines","volume":"7","author":"H Kawai","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"5","key":"pone.0347595.ref013","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/MNM.0000000000001680","article-title":"Volume-based 18 F-FDG PET analysis of cardiac sarcoidosis using the descending aorta as a reference tissue","volume":"44","author":"M Tsujimoto","year":"2023","journal-title":"Nucl Med Commun"},{"key":"pone.0347595.ref014","first-page":"921","article-title":"Examination of quantitative analysis method for cardiac amyloidosis by 99mTc-PYP scintigraphy","volume":"66","author":"S Tanahashi","year":"2021","journal-title":"Jpn J Clin Radiol"},{"issue":"3","key":"pone.0347595.ref015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12350-017-1122-6","article-title":"Volume-based glucose metabolic analysis of FDG PET\/CT: The optimum threshold and conditions to suppress physiological myocardial uptake","volume":"26","author":"O Manabe","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"pone.0347595.ref016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13550-018-0447-8","article-title":"Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?","volume":"8","author":"S Furuya","year":"2018","journal-title":"EJNMMI Res"},{"issue":"5","key":"pone.0347595.ref017","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","article-title":"Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis","volume":"21","author":"A Ahmadian","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"pone.0347595.ref018","doi-asserted-by":"crossref","first-page":"101842","DOI":"10.1016\/j.nuclcard.2024.101842","article-title":"Role of serial 18F-fludeoxyglucose positron emission tomography in determining the therapeutic efficacy of immunosuppression and clinical outcome in patients with cardiac sarcoidosis","volume":"35","author":"J Okafor","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"pone.0347595.ref019","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-8703(99)70115-8","article-title":"Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies","volume":"138","author":"A Uemura","year":"1999","journal-title":"Am Heart J"},{"key":"pone.0347595.ref020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.amjcard.2020.08.007","article-title":"Utility of Cardiac Magnetic Resonance Imaging Versus Cardiac Positron Emission Tomography for Risk Stratification for Ventricular Arrhythmias in Patients With Cardiac Sarcoidosis","volume":"134","author":"Z Gowani","year":"2020","journal-title":"Am J Cardiol"},{"issue":"2","key":"pone.0347595.ref021","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12350-016-0490-7","article-title":"The response of FDG uptake to immunosuppressive treatment on FDG PET\/CT imaging for cardiac sarcoidosis","volume":"24","author":"A Ahmadian","year":"2017","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"pone.0347595.ref022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12350-016-0682-1","article-title":"The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis","volume":"24","author":"P-I Lee","year":"2017","journal-title":"J Nucl Cardiol"},{"issue":"8","key":"pone.0347595.ref023","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00259-018-4001-8","article-title":"Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET\/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia","volume":"45","author":"D Muser","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0347595.ref024","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.jcmg.2022.05.015","article-title":"Effect of immunosuppressive therapy and biopsy status in monitoring therapy response in suspected cardiac sarcoidosis","volume":"15","author":"C Rojulpote","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"pone.0347595.ref025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjcard.2022.10.048","article-title":"Clinical outcomes of radiologic relapse in patients with cardiac sarcoidosis under immunosuppressive therapies","volume":"188","author":"K Kaneta","year":"2023","journal-title":"Am J Cardiol"},{"key":"pone.0347595.ref026","doi-asserted-by":"crossref","first-page":"133273","DOI":"10.1016\/j.ijcard.2025.133273","article-title":"Long term prognosis in cardiac sarcoidosis under FDG-PET guided immunosuppressive therapy","volume":"432","author":"Y Imamura","year":"2025","journal-title":"Int J Cardiol"},{"issue":"1","key":"pone.0347595.ref027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","article-title":"Reduction in \u00b9\u2078F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis","volume":"21","author":"MT Osborne","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"pone.0347595.ref028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.amjcard.2023.06.101","article-title":"An International Survey of Current Clinical Practice in the Treatment of Cardiac Sarcoidosis","volume":"203","author":"A De Bortoli","year":"2023","journal-title":"Am J Cardiol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:42:46Z","timestamp":1778780566000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347595"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"Lionetti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0347595","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}